JPRN-UMIN000003716
Completed
未知
Medicinal treatment on symptoms in patients with gastroesophageal reflux disease (GERD) refractory to PPIs. Multicenter, randomized, paralleled controlled study - Medicinal treatment for patients with PPIs-refractory GERD patients
Department of Internal Medicine, Saga University Hospital0 sites120 target enrollmentJune 7, 2010
ConditionsGastroesophageal reflux disease (GERD)
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Gastroesophageal reflux disease (GERD)
- Sponsor
- Department of Internal Medicine, Saga University Hospital
- Enrollment
- 120
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\) Patients with GERD which had C or D grade esophagitis diagnosed by endoscopic testing. 2\) Patients with serious complications (e.g., hepatic, renal, cardiac, pulmonary, hematological, or metabolic diseases) 3\) Patients with abscission of upper gastrointestinal tract 4\) Patients who had peptic ulcer (excusing cicatrices) or tumor. 5\) Patients with disorder in liver, gallbladder, or pancreas 6\) Patients with gastrointestinal bleeding, mechanical ileus, gastrointestinal perforation. 7\) Patients who received drugs prohibited for concomitant use during the observation period 8\) Patients who were received treatment of rabeprazole (20mg) 9\) Patients with psychoneurosis 10\) Patients with planning or during treatment of investigational drug 11\) Patients with pregnant, considering pregnancy or lactation 12\) Patients considered inappropriate by the study investigator
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Training of primary care practitioners to improve the management of common mental health disordersISRCTN16612927Instituto de Saúde Publica da Universidade do Porto (ISPUP)348
Active, not recruiting
Not Applicable
Treatment response in patients with symptoms due to gastroesophageal reflux disease either with or without esophagitis treated with pantoprazole sodium 40 mg o.d. over 8 weeks - REAL LIFEEUCTR2005-003485-42-DEycomed GmbH2,000
Active, not recruiting
Phase 1
Treatment response in patients with symptoms due to gastroesophageal reflux disease either with or without esophagitis treated with pantoprazole sodium 40 mg o.d. over 8 weeksRespuesta al tratamiento en pacientes con síntomas debidos a la enfermedad por reflujo gastroesofágico, con o sin esofagitis, tratados con 40 mg de pantoprazol sódico o.d. durante 8 semanas” - REAL LIFEEUCTR2005-003485-42-ESALTANA Pharma AG2,000
Active, not recruiting
Not Applicable
Treatment response in patients with symptoms due to gastroesophageal reflux disease either with or without esophagitis treated with pantoprazole sodium 40 mg o.d. over 8 weeks - REAL LIFEgastroesophageal reflux diseaseMedDRA version: 8.1Level: lltClassification code 10017885EUCTR2005-003485-42-ATALTANA Pharma AG2,000
Active, not recruiting
Phase 1
Treatment response in patients with symptoms due to gastroesophageal reflux disease either with or without esophagitis treated with pantoprazole sodium 40 mg o.d. over 8 weeks - REAL LIFEgastroesophageal reflux diseaseMedDRA version: 8.1 Level: llt Classification code 10017885EUCTR2005-003485-42-GBycomed GmbH2,000